Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 467

Results For "PAT"

6856 News Found

Emcure conducts oral and health check-up camps for students in Pune
Healthcare | December 20, 2022

Emcure conducts oral and health check-up camps for students in Pune

The camps were organised along with the doctors from Bharti Vidyapeeth Dental College and Hospital, Katraj, Pune, and Emcure’s occupational health centre (OHC) doctors


Cadila Pharmaceuticals appoints Ashraf Allam as Global COO
People | December 20, 2022

Cadila Pharmaceuticals appoints Ashraf Allam as Global COO

Allam was serving recently as the CEO at Public Investment Fund


Guerison to set up footprints in India’s ophthalmology market
News | December 20, 2022

Guerison to set up footprints in India’s ophthalmology market

Global pharmaceutical company having a surgical business concept incepted in Dubai


Ezharima launched in Japan as first dual EZH1 and EZH2 inhibitor therapy for leukemiaLymphoma
News | December 20, 2022

Ezharima launched in Japan as first dual EZH1 and EZH2 inhibitor therapy for leukemiaLymphoma

EZHARMIA is the fifth innovative oncology medicine to be launched in Japan by Daiichi Sankyo in the past three years


Imfinzi plus Imjudo recommended for approval in the EU by CHMP for advanced liver and lung cancers
Drug Approval | December 20, 2022

Imfinzi plus Imjudo recommended for approval in the EU by CHMP for advanced liver and lung cancers

Positive opinions based on significant survival benefit


4.4 crore health records of citizens digitized and linked with ABHA
Digitisation | December 20, 2022

4.4 crore health records of citizens digitized and linked with ABHA

This digital linking of individual’s health records with ABHA is being carried out extensively across different health facilities of the country


Astellas, Seagen and Merck announce FDA acceptance of sBLA for PADCEV for urothelial cancer
Drug Approval | December 20, 2022

Astellas, Seagen and Merck announce FDA acceptance of sBLA for PADCEV for urothelial cancer

This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting